Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RUBIVAL: Sodium Valproate in Rubinstein-Taybi Syndrome
NCT01619644Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Apr 2012
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of valproic acid in Rubinstein-Taybi syndrome (RTS), sponsored by Centre Hospitalier Universitaire de Bordeaux. Started Apr 2012; status: completed.
02
Drugs
valproic acid
03
Conditions
Rubinstein-Taybi syndrome (RTS)
Beyond the preview
Go deeper on NCT01619644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01619644.